Physician profile
Sunil Pauwaa
NPI 1710125109
$61,941.56
in general payments reported to CMS, 2019-2025
32 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,350 · 2021: $22K · 2022: $2,654 · 2023: $4,723 · 2024: $6,486 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,525 · Food and Beverage: $4,614 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,625 · Travel and Lodging: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,525.00 |
| Food and Beverage | $4,614.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,625.00 |
| Travel and Lodging | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,337.89 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $15,754.61 | 2019-2025 | |
| Abbott Laboratories | $10,080.15 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $8,828.22 | 2019-2025 | |
| Terumo Medical Corporation | $5,605.71 | 2019-2024 | Glidewire |
| Novo Nordisk INC | $660.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| United Therapeutics Corporation | $519.53 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Janssen Pharmaceuticals, INC | $359.17 | 2020-2024 | Xarelto |
| Medtronic Vascular, INC. | $330.71 | 2019-2020 | |
| Abiomed | $313.65 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $252.43 | 2023-2024 | Uptravi, Opsumit |
| Endotronix, INC. | $247.85 | 2023-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.18 | 2022-2024 | Jardiance |
| Atricure, INC. | $178.37 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boston Scientific Corporation | $171.49 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $170.42 | 2023 | Barostim Neo System |
| Ancora Heart, INC. | $166.43 | 2024 | Accucinch |
| E.R. Squibb & Sons, L.L.C. | $112.95 | 2019-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.23 | 2019-2024 | Lifevest |
| Getinge USA Sales, LLC | $92.43 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $80.06 | 2023-2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $73.11 | 2019-2023 | Amvuttra |
| Amgen INC. | $56.95 | 2021-2024 | Repatha |
| Esperion Therapeutics, INC. | $54.48 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $39.91 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $29.68 | 2024-2025 | |
| Edwards Lifesciences Corporation | $22.44 | 2022 | |
| Heartflow, INC. | $20.60 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2024 | |
| Nuwellis, INC. | $17.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.40 | 2025 | Tryvio |
| Chiesi USA, INC. | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Pauwaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.